GSK May 2024 41.000 call
| Previous close | 0.9500 |
| Open | 1.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 41.00 |
| Expiry date | 2024-05-24 |
| Day's range | 0.9500 - 1.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
BloombergGSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay
(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’One of the Last Big Bears on Wall Street Turns Bullish on US StocksFlorida’s 125% Surge in Property-
ReutersGSK whistleblower claims drugmaker cheated US government over Zantac cancer risk
(Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
- Reuters
GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales
Drugmaker GlaxoSmithKline Pharma India reported a 49% rise in fourth-quarter adjusted profit on Friday, as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. Revenue from operations rose 18% to 9.30 billion rupees, led by a 12% growth in its generic medicines portfolio which the company attributed to key focus brands Augmentin, Ceftum and Calpol. Earnings at drugmakers like GlaxoSmithKline Pharma and Abbott India have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.
